What Petrovax does

Petrovax (legal name Petrovax Pharm / Петровакс Фарм) is a Russian biopharmaceutical company founded in 1996, headquartered in Moscow (Presnenskaya naberezhnaya, 12) with a GMP production facility in the Moscow region (village of Pokrov). The company develops, manufactures, and commercializes a diversified portfolio of pharmaceutical products built around proprietary original compounds and branded formulations, including the Polyoxidonium immunomodulator (azoximer bromide), the Grippol family of influenza vaccines (Grippol Plus, Grippol Quadrivalent) and Prevenar 13 pneumococcal vaccine, the Longidaze enzyme therapy, orphan drug Fabagal, and oncology products Areima and Forsedeno Onko. The portfolio extends into dietary supplements (VitaFerr iron supplements, Venarel prenatal and reproductive health line, Omegika, Uronext, ARTNEO, Sundevit) and cosmeceuticals (Imoferaza scar care), and the company maintains an in-house R&D center supporting new product development.

The company operates a hybrid go-to-market: B2B sales to hospitals, clinics, and medical institutions through medical representatives and government procurement tenders, complemented by wholesale distribution to retail pharmacy chains serving end consumers. Distribution is national across Russia and includes a growing international export channel, with South Africa announced as a new market in June 2026. Petrovax maintains a pharmacovigilance system aligned with international and Russian Federation regulatory standards.

Petrovax is a privately held company with no public listing. The only documented external capital event is a 2014 investment by Winter Capital. The company employs between 501 and 1,000 staff and is led by President Mikhail Tsiferov. Revenue is not publicly disclosed, and the company operates without a parent company, subsidiaries, or disclosed M&A history.

Name

Petrovax

Legal name

Petrovax Pharm (Петровакс Фарм)

Website

https://petrovax.ru

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Petrovax is a Russian biopharmaceutical company (founded 1996) that develops and manufactures proprietary vaccines, immunomodulators, oncology and orphan drugs, dietary supplements, and cosmetics, selling through wholesale distributors, pharmacy chains, medical representatives, and government tenders in Russia and select export markets.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

akta.pro secondary industry

Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Biopharmaceutical products
• Influenza vaccines
• Immunomodulator drugs
• Pharmaceutical manufacturing
• Pharmaceutical R&D

Headquarters

HQ city

Naberezhnaya

HQ country

Russia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical product sales: Revenue from sale of proprietary pharmaceutical products including vaccines (Grippol Plus, Grippol Quadrivalent, Prevenar 13), immunomodulators (Polyoxidonium), specialty medicines, orphan drugs, oncology products, and cosmetics

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Petrovax researches, develops, manufactures, and markets a proprietary biopharmaceutical portfolio spanning influenza and pneumococcal vaccines (Grippol Plus, Grippol Quadrivalent, Prevenar 13), the original immunomodulator Polyoxidonium, specialty prescription medicines (Longidaze, Velson, Demefecil, Reflamaid, Forsedeno), orphan drugs (Fabagal), oncology products (Areima, Forsedeno Onko), dietary supplements (VitaFerr, Venarel Prenatal line, Omegika, Uronext, ARTNEO, Sundevit), and dermatological cosmetics (Imoferaza). The company operates its own R&D center and production facility near Moscow and exports to international markets.

Product overview

Petrovax is a biopharmaceutical company offering a diversified portfolio of pharmaceutical products, vaccines, dietary supplements, and cosmetic products. The core offerings include influenza vaccines (Grippol Plus, Grippol Quadrivalent, Prevenar 13), immunomodulators (Polyoxidonium, Longidaze), orphan drugs (Fabagal), and oncology products (Areima, Forsedeno Onko). The dietary supplement line includes women's health products (Venarel Prenatal 1, Venarel Prenatal 2, Venarel Inosit), iron supplements (VitaFerr, VitaFerr Express), and other supplements. The cosmetic portfolio includes Imoferaza for scar and skin care. The company operates an R&D center for new drug development and maintains international partnerships for export.

Differentiator

Problem solved

Functional benefit

Brands

• Гриппол® плюс: Influenza vaccine
• Гриппол® Квадривалент
• Полиоксидоний®
• Лонгидаза®
• Форседено®
• Фабагал®
• Арейма®
• Имофераза®
• ВитаФерр®

Products and services

• Grippol Plus (Гриппол® плюс) Influenza vaccine for immunization against seasonal flu, offered as part of Petrovax's vaccine portfolio for healthcare providers and end consumers.
• Grippol Quadrivalent (Гриппол® Квадривалент) Quadrivalent influenza vaccine providing broader protection against a wider range of flu virus strains than trivalent formulations, for use in flu immunization programs.
• Prevenar 13 (Превенар® 13) Pneumococcal conjugate vaccine for prevention of pneumococcal diseases, distributed as part of Petrovax's vaccine portfolio.
• Polyoxidonium (Полиоксидоний®) Proprietary immunomodulator based on azoximer bromide, used for prevention and treatment of respiratory infections and other immune-related indications. Marketed as an original development by Petrovax.
• Longidaze (Лонгидаза®) Enzyme therapy medication used in the treatment of fibrotic and inflammatory conditions, distributed by Petrovax.
• Velson (Велсон®) Pharmaceutical preparation in the Petrovax product portfolio, used for specified therapeutic applications.
• Demefecil (Демефецил) Pharmaceutical preparation marketed by Petrovax as part of its prescription medicine portfolio.
• Reflamaid (Рефламейд®) Pharmaceutical preparation marketed by Petrovax as part of its prescription medicine portfolio.
• Forsedeno (Форседено®) Pharmaceutical preparation in the Petrovax product portfolio.
• Fabagal (Фабагал®) Orphan drug for the treatment of a rare disease, marketed under Petrovax's orphan drug portfolio.
• Areima (Арейма®) Oncology medication in the Petrovax product portfolio, used in oncology care.
• Forsedeno Onko (Форседено® Онко) Oncology-specific formulation of Forsedeno, developed for oncology applications within Petrovax's product range.
• VitaFerr (ВитаФерр®) Iron dietary supplement used for the prevention and treatment of iron deficiency, sold in retail pharmacies.
• VitaFerr Express (ВитаФерр® Экспресс) Fast-acting iron supplement formulation within the VitaFerr line, marketed for iron deficiency in retail pharmacy channels.
• Uronext (Уронекст®) Dietary supplement marketed by Petrovax for urinary tract health support, available in retail pharmacy channels.
• ARTNEO (АРТНЕО®) Dietary supplement in Petrovax's consumer health portfolio.
• Sundevit (Сандевит®) Dietary supplement in Petrovax's consumer health portfolio.
• Omegika (Омегика®) Omega-3 fatty acid supplement, sold through retail pharmacies as part of Petrovax's consumer health range.
• Venarel Prenatal 1 (Венарель® Пренаталь 1) Prenatal vitamin and mineral complex designed for the first trimester of pregnancy, sold through retail pharmacies.
• Venarel Prenatal 2 (Венарель® Пренаталь 2) Vitamin and mineral complex for the second and third trimesters of pregnancy and lactation (13-40 weeks), containing iron, vitamin C, iodine, vitamin E, B vitamins, vitamin D3, omega-3, zinc, selenium and other nutrients.
• Venarel Inosit (Венарель® Инозит) Supplement containing inositol, myo-inositol, alpha-lipoic acid, D-chiro-inositol, vitamin D3, chromium, folic acid and manganese, formulated for women's reproductive system support, including PCOS and menstrual cycle disorders.
• Imoferaza (Имофераза®) Innovative cream for specialized skin care in scar and scar tissue areas, based on immobilized hyaluronidase enzyme. Designed for scar tissue care of various origins including acne, burns, injuries, plastic surgery, cosmetic procedures, and tattoo removal. Sold through retail pharmacies and consumer channels.

Segments3 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered minor and core.

• Moscow City Oncology Hospital No. 62 (Skolkovo)minorStrategic or Co-development PartnerPetrovax participated in the opening of the new complex of Moscow City Oncology Hospital No. 62 in Skolkovo, demonstrating collaboration with leading healthcare institutions.
• International pharmaceutical partnerscoreStrategic or Co-development PartnerCompany maintains international cooperation relationships and exports products to countries including South Africa. Partners include distributors and healthcare institutions in target export markets.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Generium: Russian biopharmaceutical company focused on biological products, biosimilars, and vaccines — directly comparable to Petrovax in biological products manufacturing and government-driven demand.
• BIOCAD: Russian biotech company developing and manufacturing biologics, oncology drugs, and vaccines with vertically integrated R&D and production — comparable in portfolio mix, regulatory posture, and government tender exposure.
• Valenta Pharm: Russian pharmaceutical manufacturer with a broad prescription and consumer health portfolio including immunology, respiratory, and women's health products — directly comparable to Petrovax's specialty pharma and supplement lines.
• Nanolek: Russian pharmaceutical company specializing in vaccines and biologics, including pediatric and influenza vaccines — directly comparable to Petrovax's Grippol franchise and vaccine manufacturing footprint.
• Pharmstandard: Russia's largest domestic pharmaceutical manufacturer with a comparable diversified portfolio of prescription pharma, OTC, and vaccines; directly comparable to Petrovax as the dominant local incumbent across overlapping therapeutic categories.
• ChemRar: Russian R&D-driven pharmaceutical group with operations across innovative drug development, manufacturing, and export — comparable to Petrovax in domestic innovation focus and emerging international expansion.
• R-Pharm: Leading Russian pharmaceutical company focused on innovative biotech and specialty pharmaceuticals including oncology and immunology — directly comparable to Petrovax in therapeutic focus and distribution via tenders and hospital channels.

Emerging players

• Sinovac Biotech: Emerging-market-focused vaccine manufacturer with strong influenza and pneumococcal franchise; relevant emerging player comparable to Petrovax in targeting ex-Western markets and emerging market export opportunities.

Broad incumbents

• GSK: Global pharmaceutical giant with a major vaccines franchise (Fluarix, Shingrix) and respiratory portfolio; broad incumbent setting competitive benchmarks in Petrovax's core vaccine and respiratory categories.
• Sanofi: Global vaccine leader (Fluzone, Vaxigrip) and major respiratory/immunology player; broad incumbent competing with Petrovax in influenza and pneumococcal vaccine categories globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCl_uVaTnqPpihBws-0q92HA
• LinkedInlinkedin.com/company/petrovax

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Petrovax